Anaplastic thyroid carcinoma with BRAF V600E mutation

Anaplastic thyroid carcinoma with BRAF V600E mutation is an aggressive, undifferentiated malignancy of the endocrine system arising from thyroid follicular cells It primarily affects older adults and is clinically defined by a rapidly enlarging neck mass that invades adjacent aerodigestive structures, leading to progressive hoarseness, dysphagia, dyspnea, and early distant metastases

It primarily affects older adults and is clinically defined by a rapidly enlarging neck mass that invades adjacent aerodigestive structures, leading to progressive hoarseness, dysphagia, dyspnea, and early distant metastases

Pathophysiologically, the tumor harbors an activating valine-to-glutamic acid substitution at codon 600 of the BRAF proto-oncogene This somatic gain-of-function mutation causes constitutive, ligand-independent activation of the downstream MAPK/ERK signaling cascade, accelerating aberrant cellular proliferation, dedifferentiation, and pronounced therapeutic resistance

Pathophysiologically, the tumor harbors an activating valine-to-glutamic acid substitution at codon 600 of the BRAF proto-oncogene This somatic gain-of-function mutation causes constitutive, ligand-independent activation of the downstream MAPK/ERK signaling cascade, accelerating aberrant cellular proliferation, dedifferentiation, and pronounced therapeutic resistance

This somatic gain-of-function mutation causes constitutive, ligand-independent activation of the downstream MAPK/ERK signaling cascade, accelerating aberrant cellular proliferation, dedifferentiation, and pronounced therapeutic resistance